Cellectis S.A. (EPA:ALCLS)

Market Cap	177.87M +92.5%
Revenue (ttm)	65.14M +37.2%
Net Income	-58.31M
EPS	-0.58
Shares Out	72.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	195,046
Open	2.410
Previous Close	2.450
Day's Range	2.410 - 2.554
52-Week Range	1.236 - 4.840
Beta	2.75
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 229
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCLS

Financial Performance

In 2025, Cellectis's revenue was $79.59 million, an increase of 61.72% compared to the previous year's $49.22 million. Losses were -$67.59 million, 83.9% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 23, 2026

Data Sources Report a data error